People willing to trade treatment efficacy for reduced side effects in cancer therapies
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for ...
Nov 22, 2017
0
0